Results 1 to 10 of about 61,149 (183)

Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas [PDF]

Breast Cancer Research, 2019
Background ERBB-2 is overexpressed in about 20% of breast cancers (BCs), indicating poor prognosis. The receptor activator of nuclear factor-κB (RANK) pathway is implicated in ERBB-2 (+) BC.
Ilianna Zoi, Michalis V. Karamouzis, Evangelia Xingi, Panagiotis Sarantis, Dimitra Thomaidou, Panayiotis Lembessis, Stamatios Theocharis, Athanasios G. Papavassiliou   +7 more
doaj   +2 more sources

Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer

Cell Death and Disease, 2022
Triple-negative breast cancer (TNBC) is clinically defined by the absence of estrogen and progesterone receptors and the lack of membrane overexpression or gene amplification of receptor tyrosine kinase ErbB-2/HER2.
Santiago Madera, Franco Izzo, María F. Chervo, Agustina Dupont, Violeta A. Chiauzzi, Sofia Bruni, Ezequiel Petrillo, Sharon S. Merin, Mara De Martino, Diego Montero, Claudio Levit, Gabriel Lebersztein, Fabiana Anfuso, Agustina Roldán Deamicis, María F. Mercogliano, Cecilia J. Proietti, Roxana Schillaci, Patricia V. Elizalde, Rosalía I. Cordo Russo   +18 more
doaj   +1 more source

Effect of silencing C-erbB-2 on esophageal carcinoma cell biological behaviors by inhibiting IGF-1 pathway activation

Journal of Cardiothoracic Surgery, 2021
Objective C-erbB-2 has been confirmed to be an oncogene that participates in cell growth, differentiation and division of tumors. We are wondered if its silenced expression can exert an anti-tumor effect. Therefore, this study is conducted to investigate
Zhigao Niu, Wenping Zhang, Jialun Shi, Xiangdong Li, Hanlei Wu   +4 more
doaj   +1 more source

Neuregulin promotes incomplete autophagy of prostate cancer cells that is independent of mTOR pathway inhibition. [PDF]

PLoS ONE, 2012
Growth factors activating the ErbB receptors have been described in prostate tumors. The androgen dependent prostate cancer cell line, LNCaP, expresses the ErbB-1, ErbB-2 and ErbB-3 receptor tyrosine kinases.
Eran Schmukler, Ben Shai, Marcelo Ehrlich, Ronit Pinkas-Kramarski   +3 more
doaj   +1 more source

The ErbB Signaling Network and Its Potential Role in Endometrial Cancer

Epigenomes, 2023
Endometrial cancer (EC) is the second most common malignancy of the female reproductive system worldwide. The updated EC classification emphasizes the significant role of various signaling pathways such as PIK3CA-PIK3R1-PTEN and RTK/RAS/β-catenin in EC ...
Georgios Androutsopoulos, Ioanna Styliara, Evgenia Zarogianni, Nadia Lazurko, George Valasoulis, Georgios Michail, Georgios Adonakis   +6 more
doaj   +1 more source

Identification of nucleolin as new ErbB receptors- interacting protein. [PDF]

PLoS ONE, 2008
BACKGROUND: The ErbB receptor tyrosine kinases are major contributors to malignant transformation. These receptors are frequently overexpressed in a variety of human carcinomas.
Ayelet Di Segni, Keren Farin, Ronit Pinkas-Kramarski   +2 more
doaj   +1 more source

Co-conserved features associated with cis regulation of ErbB tyrosine kinases. [PDF]

PLoS ONE, 2010
BACKGROUND: The epidermal growth factor receptor kinases, or ErbB kinases, belong to a large sub-group of receptor tyrosine kinases (RTKs), which share a conserved catalytic core.
Amar Mirza, Morad Mustafa, Eric Talevich, Natarajan Kannan   +3 more
doaj   +1 more source

Betacellulin-induced beta cell proliferation and regeneration is mediated by activation of ErbB-1 and ErbB-2 receptors.

PLoS ONE, 2011
BackgroundBetacellulin (BTC), a member of the epidermal growth factor family, is known to play an important role in regulating growth and differentiation of pancreatic beta cells.
Yoon Sin Oh, Seungjin Shin, Youn-Jung Lee, Eung Hwi Kim, Hee-Sook Jun   +4 more
doaj   +1 more source

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer

Breast Cancer: Targets and Therapy, 2021
Mohamad Adham Salkeni,1 Wajeeha Rizvi,2 Kyaw Hein,3 Gerald M Higa4 1Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; 2Department of Internal Medicine, West Virginia University ...
Salkeni MA, Rizvi W, Hein K, Higa GM
doaj  

C-erbB-2 in Serum of Patients Receiving Fractionated Paclitaxel Chemotherapy

The International Journal of Biological Markers, 1999
Humanized anti-c-erbB-2 antibodies (Herceptin®) in a weekly schedule are a new therapeutic option for the treatment of c-erbB-2-positive, advanced breast cancer (ABC).
D. Lüftner, S. Schnabel, K. Possinger
doaj   +1 more source